A B S T R A C T Factor 0, when preincubated with platelet suspensions, at concentrations as low as 1.2 ,sg/ml, inhibited thrombin-induced platelet aggregation. No inhibition of collagen or arachidonic acid-induced platelet aggregation was found. Inhibition occurred, but to a lesser extent, when thrombin and factor 0 were added to platelets at the same time.
1.2 ,sg/ml, inhibited thrombin-induced platelet aggregation. No inhibition of collagen or arachidonic acid-induced platelet aggregation was found. Inhibition occurred, but to a lesser extent, when thrombin and factor 0 were added to platelets at the same time.
No inhibition occurred when factor D was added after thrombin. Thrombin was able to overcome inhibition by factor 0 by increasing its concentration. Diisopropylphosphorofluoridate-inactivated factor 0 also inhibited thrombin-induced platelet aggregation so that enzymatic activity of factor 0 was not required for inhibition. Factor o absorbed with hirudin coupled to Sepharose 6B showed no decrease in inhibitory capacity. 125I-Factor D bound to platelets in a manner suggesting an equilibrium reaction similar to thrombin. At low factor D input, binding was linear, whereas at higher input, binding began to approach saturation. Binding of 1251-labeled thrombin to platelets was inhibited by factor D. Analysis of these data show that factor D does not alter the total number of thrombin molecules which bind to the platelet surface at saturation. However, the dissociation constant for thrombin is altered from 2.78 to 6.90 Received for publication 13 December 1978 and in revised form 1 May 1979. platelet antibodies and immune complexes activate platelets partially via classical complement pathway activation (1) (2) (3) . Zymosan treated with normal human plasma stimulates platelets to aggregate and release serotonin (4, 5) . Complement components (deposited on zymosan via alternative pathway activation), fibrinogen, and immunoglobulin (Ig)G are all required for this stimulation ofplatelets (5) (6) (7) (8) . Platelets incubated in normal human serum have been found to directly activate and bind C3 and the C5b-C9 complex (9) , and to generate C5a chemotactic activity (10) . Polley and Nachman have described C3 and C5 activation and binding to platelets in the presence of thrombin, in addition to enhancement of thrombin-induced platelet aggregation and release by C3-C9 (11) . The evidence presented in these studies suggested that C3 and C5 cleavage was not mediated by either the classical or alternative pathway convertases.
Thrombin is a potent physiologic activator of human platelets. Activation results in platelet shape changes, aggregation, and release of intracellular biologically active materials. Thrombin must bind to the platelet surface and must have proteolytic activity to induce platelet activation (12) (13) (14) (15) . The active proteolytic site is not, however, required for binding (12) . Present evidence indicates that binding occurs via specific surface receptors with different affinities for thrombin or via a single class ofreceptors which exhibits negative cooperativity (12, (14) (15) (16) . Other proteases which have been examined for activation of platelets include trypsin, chymotrypsin, plasmin, and papain (17) . Among these, only trypsin and papain were found to induce platelet secretion of calcium, and then only at relatively high concentrations.
Properdin factor 0 is a 25,000-dalton serine protease which is required for activation of the alternative complement pathway (18) (19) (20) (21) . Factor D produces limited proteolysis of its natural substrate, properdin factor B, in the presence of C3b, to yield the cleavage fragments Ba and Bb (18) (19) (20) (21) (22) . The larger fragment, Bb, and C3b form the alternative pathway convertase, C3bBb (19, 20, 23 Affinity chromatography. 220 U Hirudin (Pentapharm AG, Basel, Switzerland) (1 U/,g) was covalently linked to 2 ml cyanogen bromide-activated Sepharose 6B (Pharmacia Fine Chemicals) by the method of Parikh et al. (33) . Samples containing thrombin, factor D), or buffer alone were incubated for 1 h at 22°C with hirudin-Sepharose, and were then centrifuged at 100 g for 5 min. Supernates were removed and assayed for clotting and platelet-aggregating activity. Heparin (2.67 mg/ml Sepharose) was linked to cyanogen bromide-activated Sepharose 6B by the same technique (34) .
RESULTS

Inhibition of platelet aggregation with factor D).
Factor D concentrations ranging from 1.2 to 9.0 ,ug/ml were preincubated with platelet suspensions for 5 min at 22°C. As shown in Fig. 2A , factor D produced a definite decrease in the rate and extent of thrombininduced platelet aggregation of washed platelets, but had no effect upon platelet aggregation induced by either arachidonic acid (80 ,uM) or collagen 2 Davis, A. E., 1II. Manuscript in preparation. ( Fig. 2B) . Factor D did not induce platelet lysis, as indicated by the lack of lactate dehydrogenase activity in supernates (35) . Factor D inhibited thrombin-induced aggregation of both washed and gel-filtered platelets with equal efficiency. Platelets from different donors did show some variability both in response to thrombin and to inhibition by factor 0. Inhibition of thrombininduced platelet aggregation was confirmed with each of 15 Thrombin-factor D competition. Table I depicts the eff'ects of different quantities of factor 0 added to platelet suspensions at different times. Inhibition of aggregation was maximal when platelets were preincubated with factor 0 for 5 min before addition of thrombin. Inhibition occurred, but to a lesser extent, when thrombin and factor D were added simultaneously to the platelet suspension. No inhibition occurred if factor 0 was added after thrombin (data not shown). In other experiments, thrombin and factor D were combined and incubated for 5 min before addition to platelet suspensions. The degree of inhibition was the same as in the experiments in which thrombin and factor D were added separately but at the same time. Increasing quantities of thrombin were added to platelets which had been preincubated for 5 min with factor 0. As shown in Table I , additional thrombin was able to partially overcome the inhibition and induce a platelet response. Whereas 0.07 U/ml thrombin produced maximal aggregation in the absence of factor D, 0.17 U/ml was required with factor 0 present. Samples were maintained at 0°C for 2 h before use in aggregation experiments. Both the factor and the thrombin were >90% inactivated by hemolytic assay and by fibrinogen-clotting activity respectively. The buffer control had no eff'ect upon thrombin-induced platelet aggregation. DFP-thrombin binds to platelets in a manner indistinguishable from proteolytically active thrombin (12). 8.6 U/ml DFP-thrombin inhibited aggregation by 80% at 2.5 min, at which time control aggregation with 0.1 U/ml thrombin was complete (Fig. 3) . 9 ,ug DFP-factor D inhibited aggregation by 70% at 2.5 min. This single experiment suggests that proteolytic activity is not required for inhibition. These and the previous data suggest that factor D competes with thrombin for the same membranebinding sites.
The effect of hirudin upon the inhibition of aggregation. 1 U thrombin and 18 jig factor were each absorbed with 0.25 ml (27.6 U) settled hirudin-Sepharose. Thrombin absorbed with hirudin-Sepharose did not clot fibrinogen and did not indtuce platelet aggregation. Under the conditions used for these absorptions, the derivative thrombins produced by trypsin digestion or autolysis, are removed as efficiently as a-thrombin (data not shown). Buffer alone incubated with hirudinSepharose had no effect upon thrombin-induced platelet aggregation or upon the ability of thrombin to clot fibrinogen. Hirudin itself was therefore not being eluted from the Sepharose during incubation. Factor D absorbed with hirudin-Sepharose showed no loss in factor hemolytic activity, as has been previously reported (36) . There was no loss in the ability of' factor (9 ug) to inhibit thrombin-induced platelet aggregation after absorption. It Fig. 1 ). This contaminant was separated from factor D) by chromatography on heparin-Sepharose equilibrated in 0.05 M imidazole-HCl, pH 6.0,0.0025 M CaCl2. Under these conditions, factor D binds to heparin-Sepharose, and the lower molecular weight protein does not. The contaminating protein, at a concentration of 20 ,ug/ml did not inhibit thrombininduced platelet aggregation. Factor D, eluted from the heparin-Sepharose with 0.5 M NaCl, retained its full inhibitory activity.
Binding of 1251-factor D to platelets. Factor D radiolabeled with 1251 was incubated for 10 min with platelet suspensions. Quantities of factor D varied from 0.13 to 27.0 ,g/ml. After separation ofplatelets from medium and determination of bound and free radioactivity as described in Methods, total and platelet-bound factor D were calculated and plotted (Fig. 4) . Binding was linear at low factor 0 input and appeared to approach saturation at higher factor D input. The results shown are representative of three different experiments.
Inhibition of 1251-thrombin binding to platelets. The inhibition of '251-thrombin binding to platelets is shown in Fig. 5 . 1251-Thrombin at concentrations ranging from 0.01 to 0.10 U/ml (0.27-2.7 pmol/ml) was incubated for 1 min with platelet suspensions (2.5 x 108 platelets/ml) which had been preincubated for 10 min at 23°C, either alone or in the presence of 20 u.tg/ml factor D. All incubations were performed in quadruplicate. After incubation, platelets were separated from the suspending medium, and free and bound 125I-thrombin were determined as described in Methods. Fig. 5 depicts one of three experiments, each of which yielded very similar results. Although there were slight differences in total thrombin bound and in nonspecific binding with platelets from different donors, the degree of inhibition of thrombin binding by factor 0 was identical in the three experiments. Analysis of the binding data according to the method of Steck and Wallach (37) indicate that factor 0 is a competitive inhibitor of thrombin binding (Fig. 6) . properdin factor 0 specifically inhibits thrombinThrombin Added (mU/ml) induced platelet aggregation. Further, the data suggest that f'actor 0 and thrombin compete for the same FIGURE 5 Binding of '251-thrombin to platelets after preincubation in buffer alone and in the presence of factor f receptors on the platelet surface. The fact that pre-(20 j.g/ml). Each incubation contained 2.5 x 168 platelets/ml incubation of factor 0 with platelets results in more and the indicated concentration of thrombin in a final volume effective inhibition, and the ability to overcome of 0.325 ml of isotonic cacodylate, pH 7.35 . Incubations with inhibition with increasing thrombin concentrations are factor fD were for 10 (12, 14, 15) . In addition, factor D inhibits binding of 1251-thrombin to platelets. The number of binding sites on the platelet surface calculated from our data is slightly higher than the number reported in some previous studies (12, 14, 15) . This is very likely due to the presence of cacodylate in the buffers used in the binding studies reported here, as has been shown previously (28) . The total number ofthrombin molecules bound at saturation was not changed by factor D, whereas the apparent KdiSS for thrombin was increased, which indicates competitive inhibition. The concentration of factor 0 used in the thrombin-binding study was similar to the concentrations required to inhibit thrombin-induced platelet aggregation. The alteration of the KdiSS for thrombin by factor D (and its calculated inhibition constant) suggested that inhibition of thrombin-induced platelet aggregation is secondary to competitive inhibition of thrombin binding to the platelet surface. Factor 0 has a lower affinity for the platelet thrombin receptor than does thrombin.
Factor 0, at physiologic concentrations, would therefore be expected to interfere with thrombin action uipon platelets in situations in which low thrombin concentrations are generated. With generation of high thrombin concentrations, factor 0 would probably have no effect upon platelet-thrombin interactions.
None of the evidence suggests that the observed inhibition might be a result ofcontamination offactor D preparations with thrombin fragments. Ifan undetected thrombin fragment with an intact binding site but without proteolytic activity were present, the observed inhibition might occur. Evidence has been reported which suggests that the binding site on thrombin for hirudin is related to the binding site for platelets (39) . Absorption with hirudin-Sepharose would therefore be expected to remove any thrombin fragments which might bind to platelets and inhibit aggregation. Factor D absorbed with hirudin-Sepharose remained fully capable of inhibiting aggregation.
These data provide further evidence that factor D and thrombin are closely related proteases. Thrombin has factor D activity in a hemolytic assay and also apparently shares antigenic determinants with factor D (24) . Initial analysis of the amino acid sequence of factor D demonstrates that it is not a fragmnent of thrombin, which was suggested as one possible explanation for the above findings.2
It is not clear whether the phenomenon described here has any direct relationship with previously described complement-platelet interactions. Aside from its role in activation of the alternative pathway by zymosan, it seems unlikely the factor D is directly involved in the activation of platelets by zymosan which has been incubated in plasma (4) (5) (6) (7) (8) . In addition, no direct data are available to suggest that factor D might play a part in the activation of C3 and terminal complement components by platelets (9, 10), or by platelets in the presence of thrombin (11) . The data presented in these studies suggested, in fact, that the alternative pathway was not directly involved in these phenomena. However, the possibility that thrombin or factor D may activate a membrane-bound protease which is capable of activating C3 and C5 remains to be examined.
Although there is no direct evidence to suggest that inhibition of thrombin-induced platelet aggregation by factor D is of physiologic relevance, the amount of factor D required is well within physiologic ranges. The normal serum level of factor D, determined by radioimmunoassay, is reported to be -2 p.g/ml (25) . Factor 0, at concentrations of 1.2 ,ug/ml was capable of inhibition of aggregation. It is possible, therefore, that factor 0 may function in vivo as an inhibitor of platelet aggregation.
